跳至主要内容
临床试验/NCT05007301
NCT05007301进行中(未招募)不适用

Geko™ Cross Therapy Registry - Wound An Observational Study for the Post Market Clinical Follow-up of Safety and Patient Outcomes for Patients Undergoing Peroneal Nerve Stimulation by Geko™

Firstkind Ltd6 个研究点 分布在 2 个国家目标入组 2,500 人开始时间: 2022年4月4日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
Firstkind Ltd
入组人数
2,500
试验地点
6
主要终点
Frequency of serious adverse events

研究概览

简要总结

The geko™ Cross Therapy REGISTRY - Wound is a prospective, observational, anonymised data collection Registry with no experimental treatment that will fulfil an unmet need for an observational Registry to provide long-term clinical data to demonstrate patient benefit and regulatory compliance.

详细描述

The geko™ Cross Therapy REGISTRY - Wound represents a long-term project to integrate prospectively and systematically collected clinical data on all geko™ W wound devices (or W device variants) used in SC pathways for wound management allowing for the monitoring of patient outcomes during a follow-up period of up to four follow-up visits.

The clinical database collected for the geko™ CTR - Wound will form part of the overall post-market clinical follow-up strategy for the device and post market surveillance to support device safety and performance. There will be up to 50 contributing centres globally. Participants are asked at the time of signing up for the geko™ Cross Therapy REGISTRY - Wound (at the recruitment / baseline visit) to attend as many follow up visits as possible (up to a maximum of 4).

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Aged ≥ 18 years
  • Intact healthy skin at the site of geko™ device application.
  • Willing and able to give written informed consent
  • Presence of an ulcerative wound to the lower leg
  • Identified to receive geko™ therapy as part of their standard care for wound management.

排除标准

  • Pregnancy or breast feeding.
  • Use of any other neuro-modulation device.
  • Current use of TENS in the pelvic region, back or legs
  • Trauma to the lower limbs that would prevent geko™ from stimulating the common peroneal nerve.
  • No response to geko™ therapy i.e., no involuntary rhythmic upward and outward movement of the foot (dorsiflexion) at the maximum tolerable device setting

研究组 & 干预措施

Standard of care

Patients who are receiving the geko device as part of standard of care for wound management

干预措施: geko device (Device)

结局指标

主要结局

Frequency of serious adverse events

时间窗: Up to 12 months from study entry

Obtain frequency of serious AEs (SAEs) whether device related or not and compare rate to historic and published data i.e., geko™ therapy vs standard care without geko™ therapy

Frequency of device deficiencies

时间窗: Up to 12 months from study entry

Obtain frequency of Device Deficiencies (DD) and compare rate to historic and published data i.e., geko™ therapy vs standard care without geko™ therapy

Frequency of adverse events

时间窗: Up to 12 months from study entry

Obtain frequency of adverse events (AEs) whether device related or not and compare rate to historic and published data i.e., geko™ therapy vs standard care without geko™ therapy

次要结局

未报告次要终点

研究者

发起方
Firstkind Ltd
申办方类型
Industry
责任方
Sponsor

研究点 (6)

Loading locations...

相似试验

Geko™ Cross Therapy Registry - Wound | 临床试验